The Alpha Thalassemia Market growth is sustained by two primary, long-term factors: the increasing global population residing in endemic regions and the systematic expansion of public health screening programs. The genetic nature of the disorder means that population growth in high-prevalence zones, such as Southeast Asia and the Middle East, directly translates into a growing number of at-risk and affected individuals, ensuring a stable foundation for Alpha Thalassemia Market growth for supportive care products. This demographic factor provides a robust demand volume for essential treatments like folic acid and, critically, iron chelators required for transfusion-dependent patients.

A key accelerator of Alpha Thalassemia Market growth is the institutionalization of premarital and prenatal screening. As more governments and healthcare organizations mandate or strongly encourage genetic counseling and screening, the prevalence of Alpha Thalassemia trait and the number of infants born with severe forms ($\text{HbH}$ disease, Alpha Thalassemia Major) who survive infancy are more accurately identified. This increased diagnosis rate ensures that patients enter the clinical treatment pipeline earlier and remain under long-term management, thereby driving sustained demand for all related products and services. Moreover, the massive, non-linear growth factor is the introduction of high-value, curative gene therapies, which, while serving a small segment, disproportionately increase the total market's value. These combined factors of demographic stability, improved diagnostics, and high-value innovation create a compelling multi-faceted outlook for sustained Alpha Thalassemia Market growth.